Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRifat Ara NajninJHJian HuangTSTomasz Skórski

Discussion

Loading...

Member takes

Overview

Observational analysis reveals DNA repair mechanisms in TP53 mutated AML, suggesting potential for enhanced therapeutic strategies.

Key Points

  • AML cells with TP53 mutations exhibited increased DNA damage, highlighting treatment challenges.
  • The combination of melphalan and RAD51 inhibitors demonstrated strong efficacy against TP53 mutated AML cells.
  • Assessment using Crispr/Cas9 screens and drug sensitivity tests identified critical DNA repair vulnerabilities.
  • Targeting DNA repair pathways may improve therapeutic outcomes for patients with TP53 mutated AML.

Cite This Study

Najnin et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce5https://doi.org/10.1182/blood-2025-1498
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies2025 · 10 citations
  2. 2TP53-mutated Acute Myeloid Leukemia through a single-cell lens2025
  3. 3Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights2025
  4. 4Targeting TP53 promotes anti-leukemia immunity and enhances CD70 CAR-T efficacy in AML by transcriptionally upregulating CD702025
  5. 5Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations